Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
3.210
0.00 (0.00%)
Dec 20, 2024, 4:00 PM EST - Market closed
Arbutus Biopharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Arbutus Biopharma stock have an average target of 5.50, with a low estimate of 5.00 and a high estimate of 7.00. The average target predicts an increase of 71.34% from the current stock price of 3.21.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 20, 2024.
Analyst Ratings
The average analyst rating for ABUS stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4.5 → $5 | Strong Buy | Maintains | $4.5 → $5 | +55.76% | Nov 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +55.76% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +55.76% | Nov 7, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $4 → $4.5 | Strong Buy | Maintains | $4 → $4.5 | +40.19% | Nov 6, 2024 |
| Jefferies | Jefferies | Strong Buy Maintains $5 → $7 | Strong Buy | Maintains | $5 → $7 | +118.07% | Sep 5, 2024 |
Financial Forecast
Revenue This Year
6.31M
from 18.14M
Decreased by -65.24%
Revenue Next Year
5.30M
from 6.31M
Decreased by -15.97%
EPS This Year
-0.40
from -0.44
EPS Next Year
-0.35
from -0.40
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 7.0M | 6.2M | 8.8M | |||
| Avg | 6.3M | 5.3M | 8.6M | |||
| Low | 5.8M | 3.6M | 8.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -61.2% | -1.5% | 66.8% | |||
| Avg | -65.2% | -16.0% | 62.0% | |||
| Low | -68.1% | -42.5% | 55.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.40 | -0.32 | -0.43 | |||
| Avg | -0.40 | -0.35 | -0.42 | |||
| Low | -0.39 | -0.41 | -0.40 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.